NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Godavari Biorefineries receives patent from CNIPA
Subscribe To Our Newsletter & Stay Updated
